CHERISH
  • About Us
    • About Us
    • Our Team
    • Research Affiliates
    • —
    • Methodology Core
    • Population Data & Modeling Core
    • Dissemination & Policy Core
    • Pilot Grant & Training Core
  • News & Videos
    • News & Blog
    • Issue Briefs
    • Fact Sheets
    • Newsletters
    • Videos
  • Resources
  • Consultation Request

Cost-Effectiveness of Buprenorphine–Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse | Annals of Internal Medicine

by Michelle Papp

March 13, 2019


Tagged summary of findings

Recent Posts

Catching Up with Pilot Grant Recipient: Rachel Epstein
January 20, 2023

Addressing Statistical Issues Encountered in Conducting Prospective Economic Evaluations Alongside Clinical Trials
November 16, 2022

Engaging with People with Lived Experiences in OUD Modeling Research
October 16, 2022

Prevalence of HIV Preexposure Prophylaxis Prescribing Among Persons with Commercial Insurance and Likely Injection Drug Use
October 03, 2022

Where to Find CHERISH This Fall
September 27, 2022

CHERISH is funded by NIDA (P30DA040500) as a collaboration among Weill Cornell Medicine, Boston Medical Center, Boston University School of Public Health, University of Pennsylvania, and University of Miami Miller School of Medicine.
Copyright © 2023 CHERISH. All rights reserved.